Recent Advances in MDS and CML

Recent Advances in MDS and CML

Episodes

Specialty:

All

Year:

All

EP. 1: Introduction: Treatment Landscape of MDS

January 9th 2014

EP. 2: Discontinuation of Treatment With TKIs in CML

January 9th 2014

EP. 3: Frontline Treatment of Chronic Myelogenous Leukemia

January 9th 2014

EP. 4: Second-Generation Tyrosine Kinase Inhibitors in CML

January 9th 2014

EP. 5: Treatment Selection for Resistant or Intolerant CML

January 9th 2014

EP. 6: Hypomethylating Agents in the Treatment of High-Risk MDS

January 9th 2014

EP. 7: Role of Genetic Testing in Myelodysplastic Syndromes

January 9th 2014

EP. 8: Defining and Predicting Response to HMAs in MDS

January 9th 2014

EP. 9: Treatment of MDS Refractory to Hypomethylating Agent

January 9th 2014

EP. 10: Current and Future Treatment Landscape for MDS

January 9th 2014

EP. 11: Novel Agents and Treatment Strategies in MDS

January 9th 2014

EP. 12: Oral Azacitidine and Lenalidomide Combinations in MDS

January 9th 2014

EP. 13: Final Thoughts on Clinical Advances in MDS and CML

January 9th 2014

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC

Novel Therapies Are Poised to Answer Questions and Reinvigorate Hematologic Oncology at SOHO 2026

Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL